309 completed, 95 terminated, 90 recruiting, 47 active not recruiting. 281 Phase 2, 199 Phase 1, 60 Not applicable, 58 Phase 3, 9 Early Phase 1.
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| WELL-MPN: A Digital Lifestyle App for Patients With MPNs WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs) | Not applicable | Not yet recruiting | Brigham and Women's Hospital | 75 | 2027-01-01 | 2026-09-29 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia Luspatercept, Pacritinib - Myelofibrosis | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 50 | 2026-12-01 | 2026-11-13 |
| Jaktinib in Ruxolitinib-Treatment Failure Myelofibrosis: A Multicenter, Prospective, Real-World Observational Study Jaktinib - Myeloproliferative Neoplasms/Myelofibrosis | Not yet recruiting | Affiliated Hospital of Nantong University | 80 | 2026-11-10 | 2026-11-09 | |
| A Multicenter, Prospective, Observational Study of Jaktinib in Newly Diagnosed Myelofibrosis Jaktinib - Myeloproliferative Neoplasms/Myelofibrosis | Not yet recruiting | Affiliated Hospital of Nantong University | 80 | 2026-11-10 | 2026-11-09 | |
| Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts Momelotinib, Ruxolitinib - Myelofibrosis, Myelofibrosis (MF) | Phase 4 | Not yet recruiting | SWOG Cancer Research Network | 268 | 2026-11-01 | 2026-09-17 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Peri-Transplant Gecacitinib - Myelofibrosis, Primary Myelofibrosis (PMF) | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 46 | 2026-11-01 | 2026-10-29 |
| Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia Gecacitinib, Luspatercept - Myelofibrosis | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 31 | 2026-11-01 | 2026-11-16 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| Special Stains in Assessment of Bone Marrow Fibrosis Bone Marrow Fibrosis | Not yet recruiting | Assiut University | 60 | 2026-09-26 | 2026-10-01 | |
| Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type Blood sampling - Myelofibrosis, Acute Leukemia | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 96 | 2026-09-15 | 2026-09-04 | |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib Placebo, Elritercept - Myelofibrosis, Anemia | Phase 3 | Recruiting | Takeda | 324 | 2026-09-10 | 2026-11-06 |
| A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation - Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 46 | 2026-09-09 | 2026-10-23 |
| A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms DMR-001, Ruxolitinib - Myeloproliferative Neoplasms (MPNs) | Phase 1 | Recruiting | Damora Therapeutics | 250 | 2026-09-01 | 2026-10-27 |
| Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis ropeginterferon alfa- 2b, Ruxolitinib - Myelofibrosis | Phase 1 | Recruiting | University of Utah | 15 | 2026-08-21 | 2026-10-19 |
Showing 20 of 624. Sign in to see all of them.
Myeloproliferative Disorders (281) · Leukemia, Myeloid, Acute (223) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (207) · Myelodysplastic Syndromes (200) · Leukemia, Lymphocytic, Chronic, B-Cell (198) · Multiple Myeloma (181) · Polycythemia Vera (181) · Lymphoma, Non-Hodgkin (176) · Leukemia, Myelomonocytic, Chronic (174) · Thrombocythemia, Essential (170) · Hodgkin Disease (169) · Lymphoma, Follicular (158) · Lymphoma, Mantle-Cell (156) · Burkitt Lymphoma (151)
Hemic and Lymphatic Diseases (624) · Bone Marrow Diseases (611) · Hematologic Diseases (607) · Myeloproliferative Disorders (343) · Neoplasms (342) · Neoplasms by Histologic Type (300) · Hemorrhagic Disorders (283) · Pathological Conditions, Signs and Symptoms (280) · Leukemia, Myeloid (275) · Pathologic Processes (273) · Disease Attributes (264) · Neoplasms by Site (264) · Chronic Disease (260) · Immune System Diseases (247) · Immunoproliferative Disorders (237)
ruxolitinib (102) · Cyclophosphamide (68) · fludarabine phosphate (61) · Tacrolimus (49) · Peripheral Blood Stem Cell Transplantation (46) · Busulfan (45) · Mycophenolic Acid (40) · Whole-Body Irradiation (36) · fludarabine (30) · Antilymphocyte Serum (29) · Methotrexate (29) · Cyclosporine (27) · Melphalan (26) · Filgrastim (21) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (19)
Fred Hutchinson Cancer Center (32) · M.D. Anderson Cancer Center (32) · Novartis Pharmaceuticals (24) · City of Hope Medical Center (23) · Incyte Corporation (23) · National Cancer Institute (NCI) (17) · Case Comprehensive Cancer Center (12) · John Mascarenhas (11) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (10) · Masonic Cancer Center, University of Minnesota (10) · Mayo Clinic (10) · AbbVie (8) · Celgene (8) · Northwestern University (8) · OHSU Knight Cancer Institute (8)
United States (451) · Italy (101) · Germany (75) · France (72) · Canada (63) · United Kingdom (61) · Spain (59) · Australia (55) · Belgium (44) · China (39) · South Korea (36) · Israel (35) · Poland (35) · Hungary (27) · Japan (27)
John Mascarenhas, MD (12) · Ronald Hoffman, MD (7) · Ayalew Tefferi, MD (6) · Ryotaro Nakamura, MD (5) · Jorge Cortes, MD (4) · Ruben A. Mesa, MD (4) · Ryotaro Nakamura (4) · Srdan Verstovsek, MD (4) · Alessandro Rambaldi, MD (3)
PMID 37042865, PMID 39516087, PMID 40535755, PMID 41958363, PMID 42316774, PMID 23911705, PMID 26069290, PMID 28962635, PMID 29217781, PMID 31527168, PMID 32499241, PMID 33275766, PMID 34551507, PMID 37517413, PMID 41758981, PMID 42452788, PMID 42842696, PMID 10204198, PMID 11468154, PMID 15459300, PMID 15466923, PMID 15570084, PMID 17397698, PMID 17562873, PMID 18451242, PMID 18698002, PMID 18997171, PMID 19270260, PMID 19451433, PMID 19706886, PMID 19720904, PMID 19812383, PMID 19841031, PMID 20008298, PMID 20124511, PMID 20424252, PMID 20651074, PMID 20709666, PMID 20709904, PMID 20843246, PMID 21719601, PMID 21742281, PMID 21874061, PMID 22081489, PMID 22157574, PMID 22259028, PMID 22375970, PMID 22375971, PMID 22480131, PMID 22547163
P30CA033572 (13), P01CA108671 (12), 2023 (9), P30CA015083 (8), P30CA068485 (7), 2017 (6), P30CA006973 (6), P30CA043703 (6), 2018 (5), P30CA015704 (5), 2014 (4), 2015 (4), P01CA015396 (4), P30CA016086 (4), P30CA016672 (4)